Global Tensions as a Backdrop

Uncertainty, not Inflation may direct the Fed’s next move.

As global markets react to ripples from the Iran conflict, the Fed is expected to keep current interest rates steady. Traditional economic signals are harder to interpret in the wake of geopolitical shocks; reflexive decision making can do more harm than good (Reuters, 03/2026).

How this affects Biotech

Markets do not always respond uniformly to rate decisions. The Biotech market’s reactions are more subtle, because they are driven by innovation cycles and regulatory punctuations than borrowing costs (Marketwatch, 12/2025). Industry analysts characterize 2026 as a “catalyst rich” year for pharma and biotech, where breakthroughs (not monetary policy) like drug launches, clinical trial readouts, and regulatory decisions will drive performance (Janushenderson, 03/2026).

The Upshot

Monetary policy still matters but it’s not the principal force affecting the Biotech market. So, because of geopolitical risk and sector-specific dynamics, M&A decision makers are exercising restraint.